Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05318222 · ClinicalTrials.gov registry record · NA
Genetic Inclusion by Virtual Evaluation
A NA study of Neurodevelopmental Disorders and Birth Defects, sponsored by Baylor College of Medicine.
- Recruiting
- Registry status
- NA
- Development phase
- 200
- Enrollment target
- 1
- Study location
NCT05318222: Recruiting NA study of Neurodevelopmental Disorders and Birth Defects, sponsored by Baylor College of Medicine.
NCT05318222 is a NA study of Neurodevelopmental Disorders and Birth Defects that is actively recruiting participants, run by Baylor College of Medicine. The registered enrollment target is 200 participants, below the 574-participant average among 27 other Neurodevelopmental Disorders trials with a reported enrollment target (65% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05318222, a NA study of Neurodevelopmental Disorders and Birth Defects, is actively recruiting participants, sponsored by Baylor College of Medicine.
- RECRUITING
- Registry status
- NA
- Development phase
- 200 participants
- Enrollment target
- 1
- Study location
Study Summary
This study aims to transform the current clinical practice paradigm by leveraging an internally designed web-based model of delivery of care called Consultagene to provide remote evaluation and genomic sequencing for improving genetic health of less resourced children with rare disorders living along the Texas-Mexico border.
Conditions Studied
Interventions
- DIAGNOSTIC_TEST Whole genome sequencing (WGS)
Study Locations (1)
Texas
- University of Texas Rio Grande Valley - Edinburg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 200 participants |
| Start Date | 2022-06-01 |
| Est. Completion | 2027-01-31 |
| Phase | NA |
What NCT05318222 shows while recruiting
NCT05318222 is an interventional study that assigns participants to a tested intervention. The registered 200 participants enrollment target is mid-sized for trials with a published cap, below the 574-participant average among 27 other Neurodevelopmental Disorders trials with a reported enrollment target (65% lower).
The record links to 3 conditions, with Neurodevelopmental Disorders appearing as the primary indexed condition, and to 1 intervention - of which Whole genome sequencing (WGS) is the first listed.
NCT05318222 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT05318222 about?
NCT05318222 is a clinical study titled "Genetic Inclusion by Virtual Evaluation". This study aims to transform the current clinical practice paradigm by leveraging an internally designed web-based model of delivery of care called Consultagene to provide remote evaluation and genomic sequencing for improving genetic health of less resourced children with rare disorders living alon...
What is the current status of trial NCT05318222?
This trial is currently recruiting. It is a NA study. The enrollment target is 200 participants. The study started on 2022-06-01. Estimated completion is 2027-01-31.
What conditions does trial NCT05318222 study?
This clinical trial studies the following conditions: Neurodevelopmental Disorders, Birth Defects, Multiple Congenital Anomaly.
What interventions are being tested in trial NCT05318222?
The interventions under investigation include: Whole genome sequencing (WGS) (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT05318222?
This trial is sponsored by Baylor College of Medicine, which has 616 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05318222 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Neurodevelopmental Disorders
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05318222's enrollment target sits among peer trials
200 13th of 27 higher than 15 of 27 other Neurodevelopmental Disorders trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Neurodevelopmental Disorders trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Physical Activity and Community EmPOWERment Project
RECRUITING · NA
-
School-based Paraeducator Education for Engagement at Recess
RECRUITING · NA
-
Word Learning From Parentese in Autistic Children
RECRUITING · NA
-
HeartGPS: A Study Exploring the Effects of a Psychological Intervention for Parents and Their Babies After Prenatal Cardiac Diagnosis
RECRUITING · NA
-
Enhancing Behavior and Brain Response to Visual Targets Using a Computer Game
ACTIVE NOT RECRUITING · NA
-
AIRB-4: Self-Determined Learning Model of Instruction
ACTIVE NOT RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00107289 · 200 participants · Phase 2
Iodine I 131 Metaiodobenzylguanidine in Treating Patients With Recurrent, Progressive, or Refractory Neuroblastoma or Malignant Pheochromocytoma or Paraganglioma
- NCT00109174 · 200 participants · NA
MRS Measurement of Glutamate and GABA Metabolism in Brain
- NCT00177268 · 200 participants
Blood, Urine, and Tissue Collection for Cutaneous Lymphoma, Eczema, and Atopic Dermatitis Research
- NCT00493688 · 200 participants
A Study to Determine Whether Perioperative Energy Dynamics Correlates With Postoperative Outcomes
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI